Author: ccreplatform
-
Final Report: The Safety of Niraparib in Ovarian Cancer
The objective of this observational study is to determine if the safety profile of niraparib in real-world patient populations differs from the clinical trial findings. The need to monitor and manage adverse events means that patients must visit their health care providers more frequently. Real-world evidence may assist decision-making by supplementing the clinical trial data.…
-
Publication: Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada
Citation: Guan Q, Aktar SJ, Pataky RE, Stephen MM, Marques M, Gambaro K, Rachedi K, Forster K, Strub S, Stock D, et al. Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada. Current Oncology. 2024; 31(6):3591-3602. https://doi.org/10.3390/curroncol31060264 Abstract: Niraparib was recently funded in Canada for the maintenance treatment of ovarian cancer following platinum-based…
-
Final Report: Utilization of Cancer Therapies for Advanced Non–Small Cell Lung Cancer With an Oncogenic Driver Mutation
Recent advancements in non–small cell lung cancer (NSCLC) treatment have introduced targeted therapies for tumours with specific oncogenic mutations, offering alternatives to standard chemotherapy. However, it is uncertain if patients with advanced NSCLC who have already undergone targeted therapies and chemotherapy can benefit from immune checkpoint inhibitors. This study examined current treatment patterns and explored…
CCRE Platform 